P. Lorigan

发表

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

A. Hauschild, D. Schadendorf, K. Flaherty, 2011, The New England journal of medicine.

Improved survival with ipilimumab in patients with metastatic melanoma.

D. Schadendorf, G. Linette, J. Wolchok, 2010, The New England journal of medicine.

Improved overall survival in melanoma with combined dabrafenib and trametinib.

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, The New England journal of medicine.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

G. Linette, C. Horak, P. Ascierto, 2015, The Lancet. Oncology.

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

J. Larkin, A. Ribas, C. Blank, 2015, The New England journal of medicine.

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

J. Larkin, M. Gore, P. Lorigan, 2011, British Journal of Cancer.

Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic stage IV melanoma

J. Larkin, M. Hurwitz, M. Sznol, 2019 .

Tumorigenesis and Neoplastic Progression Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy

Caroline Dive, Lee Lancashire, Andrew Hughes, 2010 .

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

K. Nackaerts, M. Socinski, F. Shepherd, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma

M. Gore, R. Marais, P. Lorigan, 2007 .

Management of small-cell lung cancer.

C. Faivre-Finn, P. Lorigan, N. Thatcher, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma .

A. Hauschild, K. Flaherty, P. Ascierto, 2012 .

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.

M. Ranson, A. Arance, P. Lorigan, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sodium salicylate inhibits TNF-&agr;-induced NF-κB activation, cell migration, invasion and ICAM-1 expression in human melanoma cells

J. Haycock, P. Lorigan, Yifan Yang, 2006, Melanoma research.

364 First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma

J. Larkin, R. Plummer, M. Kneissl, 2014 .

Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy

M. Buyse, J. Kirkwood, A. Eggermont, 2018, Journal of the National Cancer Institute.

University of Birmingham Adjuvant interferon for the treatment of high-risk melanoma: an individual patient data meta-analysis

Ives, J. Kirkwood, C. Garbe, 2017 .

Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.

J. Kirkwood, A. Eggermont, C. Garbe, 2017, European journal of cancer.

Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence.

P. Lorigan, Cheng Han, M. Middleton, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

M. Gore, P. Lorigan, N. Thatcher, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized P hase I I S tudy o f T emozolomide G iven E very 8 Hours o r D aily W ith E ither I nterferon A lfa-2b o r T halidomide in M etastatic M alignant M elanoma

M. Ranson, A. Arance, P. Lorigan, 2003 .

Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.

D. Ettinger, R. Salgia, P. Lorigan, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).

K. Nackaerts, M. Socinski, F. Shepherd, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis

P. Lorigan, K. Ogungbenro, Alkesh Patel, 2018, Clinical pharmacology and therapeutics.

Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer.

P. Lorigan, P. Fisher, P. Kirkbride, 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).

The place of PD-1 inhibitors in melanoma management.

P. Lorigan, S. Bowyer, 2015, The Lancet. Oncology.

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022.

A. Lallas, I. Zalaudek, A. Hauschild, 2022, European journal of cancer.

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.

N. Dhomen, R. Marais, P. Lorigan, 2016, Cancer discovery.

Update on targeted therapies for small cell carcinoma of the lung

R. Griffiths, P. Lorigan, F. Blackhall, 2008, Targeted Oncology.

Update on Clinical Trials for Malignant Melanoma

P. Lorigan, L. Carter, L. Cove-Smith, 2011 .

Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma

P. Lorigan, D. French, R. Lee, 2022, British Journal of Cancer.

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

A. Hauschild, R. Dummer, K. Peris, 2018, European Journal of Cancer.

Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma.

P. Lorigan, J. Jansen, M. Ouwens, 2012, The oncologist.

The role of positron emission tomography in management of small cell lung cancer.

C. Faivre-Finn, P. Lorigan, D. Thomson, 2011, Lung cancer.

A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update

P. Lorigan, A. Marshall, J. Dunn, 2008, Ecancermedicalscience.

Current Drug Treatment Guidelines for Epithelial Ovarian Cancer

P. Lorigan, R. Coleman, T. Crosby, 1996, Drugs.

PD-L1 expression as a potential predictive biomarker.

P. Ascierto, I. Melero, P. Lorigan, 2015, The Lancet. Oncology.

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee

B. Schilling, S. Puig, V. Sondak, 2020 .

O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib

P. Hersey, R. Kefford, P. Lorigan, 2009, British Journal of Cancer.

Assessing the impact of diagnosis and the related supportive care needs in patients with cutaneous melanoma

A. Molassiotis, P. Lorigan, A. Green, 2015, Supportive Care in Cancer.

Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancer.

P. Lorigan, F. Blackhall, N. Cook, 2022, ESMO open.

Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.

V. Torri, A. Rossi, D. Galetta, 2011, Lung cancer.

Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single‐agent carboplatin in patients with poor prognosis small cell lung carcinoma

A. Arance, P. Lorigan, N. Thatcher, 2001, Cancer.

Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial.

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2012, Lung cancer.

Re: Small cell lung cancer treated in southeast Wales, Lester et al., Clin Oncol 2006;18:378-382.

C. Faivre-Finn, P. Lorigan, 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).

Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.

P. Lorigan, P. Woll, N. Thatcher, 2005, Journal of the National Cancer Institute.

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

F. Fossella, P. Lorigan, P. Woll, 2016, Investigational New Drugs.

Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma

R. Plummer, R. Andrés, L. Demidov, 2013, British Journal of Cancer.

Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2011, Lung cancer.

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

A. Hauschild, J. Kirkwood, P. Hersey, 2010, Clinical Cancer Research.

Small Cell Lung Cancer (SCLC); any progress?

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2007 .

Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial

P. Lorigan, N. Thatcher, R. Ferraldeschi, 2007, Expert review of anticancer therapy.

The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.

P. Ascierto, E. D. de Vries, Douglas B. Johnson, 2021, European journal of cancer.

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).

D. Schadendorf, P. Ascierto, R. Dummer, 2019, European journal of cancer.

Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial.

J. Larkin, A. Melcher, K. Harrington, 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006.

J. Larkin, A. Ribas, C. Blank, 2016 .

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

J. Wolchok, J. Larkin, F. Hodi, 2015 .

EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

A. Hauschild, R. Dummer, M. Gore, 2008 .

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

D. Schadendorf, K. Flaherty, P. Ascierto, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Authors’ reply to Bayley and Cave

P. Lorigan, J. Newton-Bishop, 2012, BMJ : British Medical Journal.

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

A. Bezjak, J. V. van Meerbeeck, C. Faivre-Finn, 2017, The Lancet. Oncology.

Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial.

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2011, Lung cancer.

Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2008, British Journal of Cancer.

Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance.

P. Lorigan, C. Dive, U. Keilholz, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

CIRCULATING TUMOR CELLS AS TUMOR BIOMARKERS IN MELANOMA : DETECTION METHODS AND CLINICAL RELEVANCE

P. Lorigan, C. Dive, U. Keilholz, 2014 .

Characteristics of women with recurrent molar pregnancies.

P. Lorigan, R. Coleman, S. Sharma, 2000, Gynecologic oncology.

Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022.

A. Lallas, I. Zalaudek, A. Hauschild, 2022, European journal of cancer.

Survival of patients with early invasive melanoma down‐staged under the new eighth edition of the American Joint Committee on Cancer staging system

P. Lorigan, K. Khosrotehrani, A. Green, 2019, Journal of American Academy of Dermatology.

Melanoma vaccines--they should work.

P. Lorigan, S. Danson, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer.

M. Ranson, P. Lorigan, N. Thatcher, 2005, European journal of cancer.

Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.

A. Hauschild, F. Egberts, P. Lorigan, 2009, Melanoma research.

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).

J. Haanen, P. Lorigan, S. O’Day, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma

B. Helmink, J. Wargo, L. Boon, 2020, Nature Communications.

Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancer

P. Lorigan, F. Blackhall, N. Cook, 2021, ESMO open.

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial

P. Lorigan, A. Marshall, J. Dunn, 2018, British Journal of Cancer.

Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients.

M. Gore, P. Nathan, R. Marais, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying melanomas in primary care: can we do better?

P. Lorigan, J. Newton-Bishop, 2012, BMJ : British Medical Journal.

Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities.

P. Lorigan, T. Cooksley, Avinash Gupta, 2021, European journal of cancer.

ESMO consensus conference recommendations on the management of locoregional melanoma: the ESMO Guidelines Committee.

B. Schilling, S. Puig, V. Sondak, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

13 Update on Clinical Trials for Malignant Melanoma

P. Lorigan, L. Carter, L. Cove-Smith, 2018 .

Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006.

M. Sznol, A. Arance, B. Neyns, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Emergency presentations in patients treated with immune checkpoint inhibitors.

P. Lorigan, T. Cooksley, Avinash Gupta, 2020, European journal of cancer.

Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.

J. Utikal, S. Haferkamp, D. Schadendorf, 2019, European journal of cancer.

SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy

J. Larkin, P. Carroll, P. Lorigan, 2018, Endocrine connections.

Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial

R. Plummer, H. Pandha, P. Lorigan, 2018, Oncoimmunology.

Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life?

P. Lorigan, A. Green, 2017, Nature Reviews Clinical Oncology.

Hyponatraemia secondary to nivolumab-induced primary adrenal failure

P. Lorigan, P. Trainer, P. Hulse, 2016, Endocrinology, diabetes & metabolism case reports.

Nivolumab in treating advanced melanoma

P. Lorigan, F. Gomes, 2016 .

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients

J. Larkin, R. Plummer, A. Dalgleish, 2015, Melanoma research.

Emergency management of immune‐related hypophysitis: Collaboration between specialists is essential to achieve optimal outcomes

P. Lorigan, T. Cooksley, P. Trainer, 2018, Cancer.

Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma.

R. Sullivan, P. Ascierto, J. McQuade, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Radiotherapy in extensive-disease small cell lung cancer. A survey of current UK practice.

P. Lorigan, F. Blackhall, N. Bayman, 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

Current trends in prophylactic cranial irradiation (PCI) for extensive-disease small cell lung cancer (EDSCLC): Results of a UK survey

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2008 .

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma

A. Hauschild, K. Flaherty, P. Ascierto, 2011 .

Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.

P. Lorigan, F. Blackhall, N. Thatcher, 2006, Lung cancer.

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA

N. Dhomen, R. Marais, P. Lorigan, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Acute management of the endocrine complications of checkpoint inhibitor therapy

J. Larkin, P. Carroll, P. Lorigan, 2018 .

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

D. Schadendorf, S. Puig, P. Ascierto, 2021, The Lancet. Oncology.

ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee.

B. Schilling, S. Puig, V. Sondak, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee

B. Schilling, S. Puig, V. Sondak, 2020 .

Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''

M. Millward, G. McArthur, G. Long, 2017, British Journal of Cancer.

Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies.

J. Wolchok, P. Lorigan, S. O’Day, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

James R. Anderson, J. Larkin, A. Ribas, 2018 .

Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006

N. Ibrahim, A. Ribas, C. Blank, 2017 .

Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop.

P. Lorigan, A. Eggermont, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Cutaneous Melanoma in Older Adults with Frailty

P. Lorigan, C. Donovan, S. Callaghan, 2022, Frailty in Older Adults with Cancer.

Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease

P. Lorigan, R. Coleman, B. Hancock, 2000, British Journal of Cancer.

Considerations in developing and delivering a nonpharmacological intervention for symptom management in lung cancer: the views of patients and informal caregivers.

R. Booton, J. Smith, A. Molassiotis, 2012, Journal of pain and symptom management.

P-Glycoprotein (Pgp) Expression in Resistant or Relapsing Hodgkin's Disease

P. Lorigan, M. Saber, N. Mokhtar, 2002 .

J P-glycoprotein expression in resistant or relapsing Hodgkin?s disease.

P. Lorigan, M. Saber, L. El-Helw, 2000 .

Does adjuvant vaccine therapy really have activity in malignant melanoma?

P. Lorigan, N. Ives, K. Wheatley, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

D. Schadendorf, S. Puig, P. Ascierto, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

P. Dziewulski, M. Gore, M. Highley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Cost‐effectiveness of a policy‐based intervention to reduce melanoma and other skin cancers associated with indoor tanning

K. Payne, R. Marais, P. Lorigan, 2022, The British journal of dermatology.

Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation.

P. Lorigan, N. Thatcher, J. Prendiville, 1994, European journal of cancer.

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment

J. Utikal, C. Berking, A. Hauschild, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

D. Schadendorf, S. Puig, P. Ascierto, 2019, European journal of cancer.

Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma

P. Lorigan, R. Hough, R. Molife, 2003, British Journal of Cancer.

First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM).

R. Plummer, P. Lorigan, M. Middleton, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential immunotherapy regimens-expect the unexpected.

P. Lorigan, S. Valpione, P. Serra-Bellver, 2016, The Lancet. Oncology.

LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY

G. Linette, F. Hodi, S. D'Angelo, 2014 .

Potential pitfalls in diagnosis of immunotherapy-induced hypothalamic–pituitary–adrenal axis abnormalities: a clinical case

P. Lorigan, S. Adam, Yinglai Huang, 2022, Endocrine oncology.

Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma

T. Spector, N. Segata, R. Fehrmann, 2022, EBioMedicine.

Circulating in ﬂ ammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma

T. Spector, N. Segata, R. Fehrmann, 2022 .

A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study

P. Lorigan, F. Blackhall, J. Yorke, 2021, ESMO open.

Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma.

G. Jayson, P. Lorigan, J. H. Scarffe, 1995, British Journal of Cancer.

Melanoma Cell Attachment, Invasion, and Integrin Expression is Upregulated by Tumor Necrosis Factor α and Suppressed by α Melanocyte Stimulating Hormone

J. Haycock, P. Lorigan, G. Ghanem, 2002 .

Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.

J. Larkin, A. Ribas, C. Blank, 2020 .

The n e w e n g l a n d j o u r n a l of m e d i c i n e Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

D. Schadendorf, G. Linette, J. Wolchok, 2022 .

Low‐dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue

P. Lorigan, P. Johnson, D. Linch, 2007, British journal of haematology.

Tumour infiltrating B cells discriminate checkpoint blockade-induced responses.

Graham M Lord, P. Mundra, N. Dhomen, 2022, European journal of cancer.

Sunbed Use among 11- to 17-Year-Olds and Estimated Number of Commercial Sunbeds in England with Implications for a ‘Buy-Back’ Scheme

K. Payne, P. Lorigan, M. Eden, 2021, Children.

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.

L. Pickering, Douglas B. Johnson, C. Blank, 2022, European journal of cancer.

CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS).

A. Bezjak, C. Faivre-Finn, P. Lorigan, 2016 .

Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate.

P. Lorigan, R. Coleman, J. Waterhouse, 1997, British Journal of Cancer.

Small cell carcinoma of the cervix.

P. Lorigan, R. Coleman, E. Sheridan, 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

M. Weichenthal, K. Kähler, P. Ascierto, 2022, Journal for ImmunoTherapy of Cancer.

Reasons for using indoor tanning devices: A systematic review of qualitative evidence

K. Payne, P. Lorigan, M. Eden, 2022, British journal of health psychology.

Survival Benefits from Follow-Up of Patients with Lung Cancer: A Systematic Review and Meta-Analysis

P. Lorigan, D. Hind, M. Lloyd-Jones, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma

P. Lorigan, H. Heimann, Gerard Reid, 2019, Ocular immunology and inflammation.

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

A. Hauschild, D. Schadendorf, P. Ascierto, 2017, European journal of cancer.

Abstract 9035: An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients

R. Plummer, P. Lorigan, P. Patel, 2015 .

Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and goo

A. Bezjak, C. Faivre-Finn, P. Lorigan, 2016, BMJ Open.

A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma

A. Hauschild, A. Arance, C. Garbe, 2014, Cancer.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

A. Ribas, C. Blank, A. Arance, 2017, The Lancet.

Gestational choriocarcinoma of the ovary diagnosed by analysis of tumour DNA.

P. Lorigan, A. Grierson, J. Goepel, 1996, Cancer letters.

Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma.

A. Molassiotis, P. Lorigan, A. Green, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Revised UK guidelines for the management of cutaneous melanoma 2010.

M. Gore, P. Nathan, P. Lorigan, 2010, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

Revised U.K. guidelines for the management of cutaneous melanoma 2010

P. Nathan, P. Lorigan, R. MacKie, 2010, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

Surrogate endpoints in advanced sarcoma trials: a meta-analysis

J. Blay, S. Litière, J. Verweij, 2018, OncoTarget.

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

J. Larkin, A. Ribas, C. Blank, 2019, The Lancet. Oncology.

Melanoma cell attachment, invasion, and integrin expression is upregulated by tumor necrosis factor alpha and suppressed by alpha melanocyte stimulating hormone.

J. Haycock, P. Lorigan, G. Ghanem, 2002, The Journal of investigative dermatology.

Systemic therapy for metastatic malignant melanoma – from deeply disappointing to bright future?

A. Hauschild, P. Lorigan, T. Eisen, 2008, Experimental dermatology.

Gender and survival in malignant tumours.

P. Lorigan, S. Macneil, R. Molife, 2001, Cancer treatment reviews.

Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014

Martin F. Mihm, B. Schilling, F. Marincola, 2013, Journal of Translational Medicine.

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

K. Savage, J. Wolchok, J. Larkin, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma

B. Helmink, J. Wargo, L. Boon, 2020, Nature Communications.

Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

J. Blay, S. Rodenhuis, M. van Glabbeke, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

Dirk Schadendorf, Alessandro Testori, Axel Hauschild, 2014, The Lancet. Oncology.

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.

S. Dawson, M. Dawson, N. Dhomen, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

N. Dhomen, R. Marais, P. Lorigan, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials.

A. Hauschild, D. Schadendorf, K. Flaherty, 2014, The Lancet. Oncology.

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.

O. S. Nielsen, J. Blay, S. Rodenhuis, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

D. Schadendorf, S. Puig, P. Ascierto, 2020, JAMA oncology.

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

D. Schadendorf, S. Puig, P. Ascierto, 2018, The New England journal of medicine.

Survival of patients with advanced metastatic melanoma: The impact of novel therapies.

A. Hauschild, D. Schadendorf, S. Ugurel, 2016, European journal of cancer.

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR

M. Esteller, K. Flaherty, Dennie T. Frederick, 2015, Nature Medicine.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling

Samra Turajlic, Richard Marais, M. Gore, 2014, Science Signaling.

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

M. Gore, C. Jørgensen, C. Springer, 2013, Cancer discovery.

Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients

P. Mundra, N. Dhomen, R. Marais, 2018, European journal of cancer.

No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients

R. Marais, P. Lorigan, M. R. Girotti, 2014, Molecular oncology.

Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study).

P. Ascierto, A. Testori, M. Maio, 2012, European journal of cancer.

Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).

A. Levy, A. Testori, M. Maio, 2012, European journal of cancer.

Efficacy of vemurafenib in BRAFV600K mutation positive melanoma disease - results from the phase III clinical study BRIM-3.

A. Hauschild, K. Flaherty, P. Ascierto, 2011 .

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

R. Soffietti, N. Shemesh, J. Bosch-Barrera, 2022, Nature Medicine.

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma

T. Spector, P. Manghi, N. Segata, 2022, Nature Medicine.

Management of Small Cell Lung Cancer

Corinne Faivre-Finn, C. Faivre-Finn, P. Lorigan, 2005, Drugs.

Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells

G. Margison, P. Lorigan, N. Thatcher, 2011, Melanoma research.

Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.

M. Ranson, G. Margison, P. Lorigan, 2004, Molecular cancer therapeutics.

Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer

N Thatcher, M. Ranson, G. Margison, 2006, British Journal of Cancer.

Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis

P. Lorigan, S. Jagdev, R. Coleman, 1999, British Journal of Cancer.

Guidelines for the stratification of patients recruited to trials of therapy for low-risk gestational trophoblastic tumor.

P. Lorigan, R. Coleman, B. Hancock, 2000, Gynecologic oncology.

High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia

M. Seckl, P. Lorigan, E. Kanfer, 2005, British Journal of Cancer.

DGAT1 is a lipid metabolism oncoprotein that enables cancer cells to accumulate fatty acid while avoiding lipotoxicity

C. Ceol, W. Dunn, A. Jankevics, 2020, bioRxiv.

Tumour lysis syndrome, case report and review of the literature.

P. Lorigan, J. Howard Scarffe, G. Morgenstern, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Thoracic radiation therapy for limited-stage small-cell lung cancer: unanswered questions.

C. Faivre-Finn, P. Lorigan, C. West, 2005, Clinical lung cancer.

Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization

P. Lorigan, G. Wilson, J. Goepel, 2002, British journal of haematology.

The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival

P. Mundra, N. Dhomen, R. Marais, 2021, Nature Communications.

Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

J. Hipp, C. Horak, G. Botti, 2016, Drugs.

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

N. Curtin, R. Plummer, P. Lorigan, 2013, Cancer Chemotherapy and Pharmacology.

Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma

P. Lorigan, R. Hough, J. Goepel, 2001, British Journal of Cancer.

Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma

P. Lorigan, C. Dive, G. Clack, 2014, Melanoma research.

Modern Management of Small-Cell Lung Cancer

C. Faivre-Finn, P. Lorigan, N. Thatcher, 2012, Drugs.

Novel Therapies for the Treatment of Small-Cell Lung Cancer

P. Lorigan, N. Thatcher, R. Board, 2012, Drugs.

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.

C. Fink, A. Dingemans, J. V. van Meerbeeck, 2011, European journal of cancer.

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

Michael Thomas, Yi-long Wu, E. Felip, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advances in the management of melanoma: targeted therapy, immunotherapy and future directions

P. Lorigan, E. Dean, 2012, Expert review of anticancer therapy.

G. Linette, D. Revicki, P. Lorigan, 2012, Health and Quality of Life Outcomes.

Abstract CT231: Nivolumab and ipilimumab +/- UV1 vaccine as 1stline treatment in patients with malignant melanoma (INITIUM-trial)

P. Lorigan, S. O’Day, M. Nyakas, 2021, Clinical Trials.

Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement.

J. Larkin, P. Nathan, P. Lorigan, 2020, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

TNF-α increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes

P. Lorigan, S. Macneil, G S Evans, 2003, British Journal of Cancer.

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

Z. Szallasi, T. Schumacher, J. Larkin, 2014, Cancer Immunology, Immunotherapy.

A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1).

N Thatcher, R. Booton, D. Dunlop, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

MDR-1 expression in non-Hodgkin's lymphomas is unrelated to treatment intensity or response to therapy.

P. Lorigan, J. Royds, J. Goepel, 1995, Leukemia & lymphoma.

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

A. Hauschild, D. Schadendorf, S. Ugurel, 2017, European journal of cancer.

Explorer Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells

M. Weller, O. Sansom, C. Cui, 2017 .

High-risk cutaneous melanoma follow-up: time for more intensive surveillance?

J. Larkin, P. Lorigan, Michael Davidson, 2014, Melanoma management.

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.

D. Schadendorf, R. Dummer, A. Arance, 2013, The Lancet. Oncology.

Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

M. Weichenthal, J. Utikal, D. Schadendorf, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

P. Ascierto, Douglas B. Johnson, C. Blank, 2021, The Lancet. Oncology.

Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer.

P. Lorigan, F. Thistlethwaite, F. Blackhall, 2019, The oncologist.

Platinum-based chemotherapy with thoracic radiotherapy in stage III good performance status non-small cell lung cancer patients

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2005 .

Sequential Platinum-Based Chemotherapy-Thoracic Radiotherapy in Early Stage Non–Small Cell Lung Cancer

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2005, Clinical Cancer Research.

Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status

D. Smith, P. Lorigan, N. Thatcher, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East

P. Ascierto, V. Chiarion Sileni, P. Lorigan, 2021, International journal of cancer.

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

A. Hauschild, K. Flaherty, P. Ascierto, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

M. Gore, P. Nathan, R. Marais, 2011, British Journal of Cancer.

Checkpoint inhibitor‐associated bullous cutaneous immune‐related adverse events: a multicentre observational study *

J. Larkin, P. Lorigan, Aakriti Gupta, 2022, The British journal of dermatology.

Dabrafenib and its use in the treatment of metastatic melanoma.

P. Lorigan, R. Lee, S. Bowyer, 2015, Melanoma management.

Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients.

P. Lorigan, N. Ives, R. Stowe, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting angiogenesis in melanoma

P. Lorigan, R. Ferraldeschi, 2009 .

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

J. Larkin, M. Gore, C. Fisher, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

J. Larkin, R. Plummer, P. Nathan, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.

P. Lorigan, M. Howell, S. Bowyer, 2015, Lung cancer.

LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial

D. Schadendorf, K. Flaherty, P. Ascierto, 2020 .

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

D. Schadendorf, G. Linette, C. Horak, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

A. Hauschild, P. Ascierto, J. Larkin, 2019, European journal of cancer.

Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma

J. Larkin, M. Gore, P. Lorigan, 2018, ESMO Open.

Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy

Piyushkumar A. Mundra, Sara Valpione, Richard Marais, 2019, Nature Cancer.

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

M. Gore, P. Nathan, P. Lorigan, 2014, The Lancet. Oncology.

The role of chemotherapy in the modern management of melanoma.

P. Lorigan, R. Lee, S. Bowyer, 2014, Melanoma management.

Immunotherapy Bridge 2021 and Melanoma Bridge 2021: meeting abstracts

R. Sullivan, R. Dummer, J. Kirkwood, 2022, Journal of Translational Medicine.

Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019.

A. Hauschild, D. Schadendorf, J. Becker, 2020, European journal of cancer.

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.

A. Lallas, I. Zalaudek, A. Hauschild, 2022, European journal of cancer.

Consensus Guidelines for the Management of Melanoma during the COVID-19 Pandemic: Surgery, Systemic Anti-cancer Therapy, Radiotherapy and Follow-up

P. Lorigan, H. Peach, A. Rembielak, 2020, Clinical Oncology.

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

A. Hauschild, R. Dummer, K. Peris, 2018, European journal of cancer.

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

A. Hauschild, G. Linette, J. Kirkwood, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma

P. Lorigan, N. Thatcher, M. Middleton, 2000, British Journal of Cancer.

Anti-Angiogenesis Therapy for Melanoma

P. Lorigan, R. Ferraldeschi, 2012 .

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.

M. Weichenthal, A. Hauschild, D. Schadendorf, 2018, European journal of cancer.

The role of nivolumab in melanoma.

P. Lorigan, F. Gomes, P. Serra-Bellver, 2018, Future oncology.

Integrating radiation therapy with emerging systemic therapies: Lessons from a patient with cerebral radionecrosis, spinal cord myelopathy, and radiation pneumonitis.

P. Lorigan, G. Whitfield, R. Hawkins, 2016, Practical radiation oncology.

Vemurafenib-induced nonautoimmune haemolytic anaemia.

M. Dennis, P. Lorigan, J. Hodgetts, 2014, Melanoma research.

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

D. Schadendorf, S. Puig, P. Ascierto, 2021, The Lancet. Oncology.

Circulating Tumour DNA in Melanoma—Clinic Ready?

P. Lorigan, D. Rothwell, A. Tivey, 2022, Current Oncology Reports.

Adjuvant immunotherapy: the sting in the tail.

A. Eggermont, P. Lorigan, P. Trainer, 2020, European journal of cancer.

Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): An individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts).

J. Kirkwood, A. Eggermont, C. Garbe, 2014 .

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma

N. Carragher, S. Whittaker, C. Springer, 2017, Cancer cell.

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma

N. Carragher, S. Whittaker, C. Springer, 2015, Cancer cell.

UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma.

J. Larkin, P. Nathan, P. Lorigan, 2016 .

CheckMate 067: Long-term outcomes in patients with mucosal melanoma.

P. Ascierto, R. Dummer, J. Larkin, 2020 .

Phase 1/2 Study of the CD56‐Targeting Antibody‐Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small‐Cell Lung Cancer Patients With Extensive‐Stage Disease

M. Socinski, F. Kaye, P. Ellis, 2017, Clinical lung cancer.

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.

T. Eisen, W. Miller, S. Leyvraz, 2009, Lung cancer.

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).

D. Schadendorf, P. Ascierto, R. Dummer, 2019, European journal of cancer.

Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors

I. Puzanov, J. Haanen, P. Lorigan, 2021, Journal for ImmunoTherapy of Cancer.

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

D. Schadendorf, S. Puig, P. Ascierto, 2022, European journal of cancer.

Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma

Crispin J. Miller, N. Carragher, P. Mundra, 2020, ESMO Open.

Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma

R. Fehrmann, G. Hospers, E. de Vries, 2023, BMC Cancer.

Immune checkpoint inhibitor-mediated hypophysitis: no place like home.

P. Lorigan, T. Cooksley, J. Ho, 2023, Clinical medicine.

Emergency ambulatory outpatient management of immune-mediated hypophysitis

P. Lorigan, T. Cooksley, T. Knight, 2020, Supportive Care in Cancer.

Investigation of female survival benefit in metastatic melanoma

P. Lorigan, J. Miller, A. Price, 1999, British Journal of Cancer.

Advances in the treatment of late stage melanoma

P. Lorigan, S. Danson, L. Walkington, 2013, BMJ.

Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab

P. Lorigan, D. du Plessis, H. Chinoy, 2018, BMJ Case Reports.

Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance.

P. Lorigan, C. Dive, U. Keilholz, 2015 .

Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.

M. Socinski, E. Smit, P. Lorigan, 2012, Lung cancer.

Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery.

Crispin J. Miller, Tim Yates, Phil Chapman, 2014, Cancer research.

Improving Outcomes in Advanced Malignant Melanoma

P. Lorigan, S. Danson, 2012, Drugs.

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

A. Hauschild, S. Puig, R. Fisher, 2021, European journal of cancer.

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.

S. Dawson, M. Dawson, N. Dhomen, 2019 .

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

O. S. Nielsen, S. Rodenhuis, M. van Glabbeke, 1999, European journal of cancer.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, David C. Smith, A. Hauschild, 2016, Journal of Translational Medicine.

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells

M. Weller, O. Sansom, C. Cui, 2016, Oncotarget.

A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

A. Hauschild, J. Kirkwood, P. Hersey, 2008 .

mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

A. Hauschild, D. Schadendorf, R. Dummer, 2014 .

The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit.

R. Stephens, F. Shepherd, M. Nankivell, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine

D. Schadendorf, A. Harris, P. Lorigan, 2010, Cancer Immunology, Immunotherapy.

Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update.

D. Ettinger, P. Lorigan, D. Spigel, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meeting report: consensus from the first and second Global Workshops in Melanoma November 19–20, 2008

A. Hauschild, D. Schadendorf, A. Halpern, 2009, Pigment cell & melanoma research.

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

M. Millward, G. McArthur, G. Long, 2016, British Journal of Cancer.

Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study

A. Dalgleish, A. Maraveyas, P. Lorigan, 2014, The British journal of dermatology.

The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma

P. Lorigan, F. Sampson, S. Beard, 1999, British Journal of Cancer.

Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.

Nick Thatcher, Shengyan Hong, Jacek Jassem, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum lactate dehydrogenase (LDH) as a prognostic selection criterion for ipilimumab treatment in metastatic melanoma

Z. Szallasi, T. Schumacher, J. Larkin, 2013 .

A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre

A. Molassiotis, R. Cowan, A. Wardley, 2008, Supportive Care in Cancer.

A qualitative exploration of a respiratory distress symptom cluster in lung cancer: cough, breathlessness and fatigue.

A. Molassiotis, P. Lorigan, F. Blackhall, 2011, Lung cancer.

Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.

P. Ascierto, Douglas B. Johnson, G. Long, 2021, The Lancet. Oncology.

Lung cancer after treatment for Hodgkin's lymphoma: a systematic review.

A. Howell, J. Radford, P. Lorigan, 2005, The Lancet. Oncology.

Cumulative antibiotic use and efficacy of immune checkpoint inhibitors in patients with advanced cancer.

P. Lorigan, F. Thistlethwaite, F. Blackhall, 2018 .

Chemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer.

P. Lorigan, D. Betticher, N. Thatcher, 1995, Seminars in oncology.

SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)

R. Plummer, S. Leyvraz, P. Lorigan, 2019, Annals of Oncology.

The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials.

R. Booton, F. Shepherd, A. Hackshaw, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Reasons for indoor tanning use and the acceptability of alternatives: A qualitative study.

P. Lorigan, A. Green, T. Epton, 2021, Social science & medicine.

Lung cancer after treatment for breast cancer.

A. Howell, C. Faivre-Finn, P. Lorigan, 2010, The Lancet. Oncology.

A rational approach to dose optimisation of pembrolizumab and nivolumab using cost analysis and pharmacokinetic modelling and simulation

P. Lorigan, K. Ogungbenro, Alkesh Patel, 2016 .

Primary intracerebral lymphoma: A clinicopathological study of 28 patients.

P. Lorigan, R. Hough, M. Robinson, 1999, International journal of oncology.

Monitoring tumour cells in the peripheral blood of small cell lung cancer patients.

J Lawry, P. Lorigan, J. Lawry, 2002, Cytometry.

Thoracic radiotherapy for limited-stage small-cell lung cancer: controversies and future developments.

C. Faivre-Finn, P. Lorigan, C. West, 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

Considerations in developing and delivering a non-pharmacological intervention for symptom management in lung cancer: the views of health care professionals

R. Booton, J. Smith, A. Molassiotis, 2012, Supportive Care in Cancer.

Unmet supportive care needs, health status and minimum costs in survivors of malignant melanoma

A. Molassiotis, P. Lorigan, L. Davies, 2018, European journal of cancer care.

Enhanced Fatty Acid Scavenging and Glycerophospholipid Metabolism Accompany Melanocyte Neoplasia Progression in Zebrafish.

H. Spaink, W. Dunn, Shuning He, 2019, Cancer research.

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma

D. Schadendorf, P. Ascierto, A. Eggermont, 2022, NEJM Evidence.

Adjuvant therapy for Stage 2 melanoma: the need for further studies

C. Garbe, M. Mandalà, G. Long, 2023, European Journal of Cancer.

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

D. Schadendorf, P. Ascierto, C. Blank, 2023, European journal of cancer.

Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma

N. Segata, R. Fehrmann, G. Hospers, 2023, JAMA oncology.

The role for chemotherapy in the modern management of melanoma.

P. Lorigan, Avinash Gupta, F. Gomes, 2017, Melanoma management.

Radiotherapy for small-cell lung cancer-Where are we heading?

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2009, Lung cancer.

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study

P. Ascierto, M. Mandalà, P. Lorigan, 2021, Journal for ImmunoTherapy of Cancer.

Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC)

K. Nackaerts, M. Socinski, F. Shepherd, 2012 .

A Guideline for the Management of Gastrointestinal Stromal Tumour (GIST)

I. Judson, P. Lorigan, R. Grimer, 2002, Sarcoma.

Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial

A. Hauschild, D. Schadendorf, K. Flaherty, 2011 .

Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.

P. Lorigan, C. Dive, J. Cummings, 2013, The Journal of investigative dermatology.

Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma.

J. Larkin, P. Nathan, P. Lorigan, 2013 .

510 POSTER Phase I study of IMGN901 (BB-10901) in patients with CD56-positive solid tumours

F. Fossella, P. Lorigan, P. Woll, 2008 .

Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.

M. Socinski, G. Scagliotti, E. Smit, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Biochemotherapy versus chemotherapy for metastatic malignant melanoma: A meta-analysis of the randomised trials

P. Lorigan, N. Ives, R. Stowe, 2007 .

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

J. Larkin, R. Plummer, M. Kneissl, 2023, Cancer Chemotherapy and Pharmacology.

Abstract B237: Clinical experience of IMGN901 (BB‐10901, huN901‐DM1) in patients with Merkel cell carcinoma (MCC)

F. Fossella, P. Lorigan, P. Woll, 2009 .

Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.

J. Larkin, A. Ribas, C. Blank, 2017 .

Efficacy results from a phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors.

L. C. Chen, F. Fossella, P. Lorigan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T cell immune awakening in response to immunotherapy is age-dependent

N. Dhomen, R. Marais, P. Lorigan, 2021, European journal of cancer.

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

C. Berking, A. Hauschild, D. Schadendorf, 2021, Journal for ImmunoTherapy of Cancer.

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma

R. Plummer, M. Churchman, P. Nathan, 2013 .

Expanded access programmes: patient interests versus clinical trial integrity.

A. Hauschild, D. Schadendorf, V. Sondak, 2015, The Lancet. Oncology.

Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.

M. Gore, P. Nathan, P. Lorigan, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial

P. Lorigan, A. Marshall, J. Dunn, 2018, British Journal of Cancer.

Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma

James R. Anderson, J. Larkin, A. Ribas, 2019, Clinical Trials.

Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma.

M. Atkins, P. Lorigan, S. Agarwala, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study

P. Ascierto, J. Kirkwood, A. Shoushtari, 2023, Journal for ImmunoTherapy of Cancer.

Randomised phase III trial of docetaxel/carboplatin vs MIC/MVP chemotherapy in advanced non-small cell lung cancer (NSCLC) - final results of a British Thoracic Oncology Group (BTOG) trial.

R. Booton, K. O'Byrne, C. Faivre-Finn, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)

A. Hauschild, P. Ascierto, P. Queirolo, 2020 .

On the potential beneficial effects of indoor tanning: reply from the authors

K. Payne, R. Marais, P. Lorigan, 2022, British Journal of Dermatology.

Abstract 4167: Ultraviolet radiation cooperates with individual oncogenes to drive melanomagenesis through distinct molecular mechanisms

J. Reis-Filho, R. Marais, P. Lorigan, 2016 .

PP-16 Does a wound healing environment and the inflammation associated with it promote melanoma invasion?

S. MacNeil, J. Haycock, P. Lorigan, 2003 .

Improving survival with thoracic radiotherapy in patients with small cell lung cancer. The CONVERT and the REST Trials.

C. Faivre-Finn, P. Lorigan, F. Blackhall, 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023.

A. Lallas, I. Zalaudek, A. Hauschild, 2023, European journal of cancer.

Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).

D. Schadendorf, P. Ascierto, R. Dummer, 2017 .

Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma

J. Larkin, A. Ribas, C. Blank, 2015 .

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.

A. Lallas, I. Zalaudek, A. Hauschild, 2023, European journal of cancer.

CAcTUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma.

R. Marais, P. Lorigan, C. Dive, 2021 .

Asthma in pregnancy complicated by iatrogenic pulmonary oedema.

P. Lorigan, A. Ratcliffe, K. B. Carroll, 1989, Postgraduate medical journal.

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

A. Hauschild, D. Schadendorf, P. Ascierto, 2023, Nature Medicine.

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma.

A. Hauschild, K. Flaherty, P. Ascierto, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy.

P. Lorigan, S. Leachman, A. Tarhini, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Applying Best-Worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer.

Richard Emsley, Darren Ashcroft, Alex Molassiotis, 2012, Lung cancer.

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma

N. Carragher, S. Whittaker, C. Springer, 2017, Cancer cell.

767O TREATMENT OF PATIENTS WITH ADVANCED REFRACTORY OR RELAPSED MELANOMA IN A PHASE II STUDY OF TREMELIMUMAB (CP-675,206), AN ANTI-CTLA4 MONOCLONAL ANTIBODY

A. Hauschild, D. Schadendorf, H. Pehamberger, 2008 .

Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study.

M. Weichenthal, A. Hauschild, D. Schadendorf, 2017 .

BRAF +/- MEK inhibition following pembrolizumab (pembro) in KEYNOTE-006

A. Ribas, C. Blank, J. Schachter, 2018 .

Extensive-stage small-cell lung cancer--moving beyond response rate?

P. Lorigan, R. Ferraldeschi, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.